ASV AGEN2017 + QS-21 Stimulon

**ASV AGEN2017 + QS-21 Stimulon** is a personalized neoantigen cancer vaccine formulation being investigated primarily for the prevention of relapse in patients with solid tumors after surgical resection[1][4][5]. The vaccine is based on the AutoSynVax (ASV) platform, which utilizes tumor neoantigens identified uniquely from each patient’s tumor using next-generation sequencing and proprietary computational algorithms. Selected immunogenic peptides are formulated into the vaccine, often complexed with heat shock proteins, and administered with QS-21 Stimulon, a saponin-based adjuvant derived from Quillaja saponaria. QS-21 Stimulon enhances immune responses by promoting antigen-presenting cell activation and a Th1-biased cellular immune response, partly via inflammasome activation[4][7][9]. The formulation aims to induce strong, durable, tumor-specific T-cell responses. ASV® AGEN2017 + QS-21 Stimulon has completed early stage clinical trials, including for safety and tolerability in patients at risk of tumor relapse following complete tumor resection[1][5]. The developer is Agenus. QS-21 Stimulon is also developed and supplied by Agenus under the Stimulon brand[4][6].

Brand names

AutoSynVaxQS-21 StimulonQS21 StimulonQS 21 Stimulon

Other names

AutoSynVax AGEN2017 + QS-21 StimulonASV® AGEN2017 with QS-21 Stimulon® Adjuvant